II. Causes: Negative
- Normal titer less than 1:20 dilution
- See interpretation below regarding titers
III. Causes: Positive
- Normal patient without underlying abnormality: 3-30%
- More common in older women
- Rheumatologic Conditions
- Infection
- Tuberculosis
- Chronic active hepatitis (e.g. Hepatitis C)
- Subacute Bacterial Endocarditis
- HIV Infection
- Miscellaneous Conditions
- Type I Diabetes Mellitus
- Hashimoto Thyroiditis
- Multiple Sclerosis
- Pulmonary fibrosis
- Silicone gel implants
- Pregnant women
- Elderly patients
- Medications (Drug induced Lupus Erythematosus)
IV. Mechanism
- IgG or IgM Antinuclear Antibody (ANA)
- Antibody binds to nuclei or nuclear components
V. Precautions
- Almost all patients with Systemic Lupus Erythematosus (SLE) have a positive ANA titer
- Most patients with a positive ANA titer do not have Systemic Lupus Erythematosus (SLE)
- High False Positive Rate (esp. low titers) and in Autoimmune Conditions (see above)
- ANA Levels fluctuate and do not correlate with response to therapy or with disease activity
- Once ANA test is positive, repeat testing is rarely indicated
VI. Labs: Indirect Immunofluorescence Assay (IIF) Slide test
- Uses fixed and permeabilized human epithelial cells (HEp-2 cells)
- Labor intensive
- Most accurate ANA Test
- Test Sensitivity: 93%
- Test Specificity: 57%
- Positive Likelihood Ratio (LR+) for SLE: 2.2
- Negative Likelihood Ratio (LR-) for SLE: 0.1
- Measures direct binding
- Patient's serum antibodies to cell nuclei
- Specific components of cell nucleus are also bound
- See ANA subunits below
VII. Labs: Enzyme-Linked Immunosorbent Assay (ELISA)
- Less labor intensive and less costly than Indirect Immunofluorescence Assay (IIF) Slide Test
- Less accurate than Indirect Immunofluorescence Assay (IIF) Slide Test
- Test Sensitivity: 81.9%
- Test Specificity: 79.6%
- Positive Likelihood Ratio (LR+) for SLE: 2.97
- Negative Likelihood Ratio (LR-) for SLE: 0.25
VIII. Interpretation: Titer (Dilution)
- Pretest probability affects interpretation
- Primary Care Setting: 2% SLE probability
- Rheumatology Setting: 30% SLE probability
- Low Positive (1:160 or lower): Low significance
- SLE Likelihood: <2% (<26% for rheumatologists)
- High Positive (1:320 or higher): Higher significance
- SLE Likelihood: 2-17% (32-81% for rheumatologists)
- References
IX. Interpretation: ANA Staining Patterns
- Systemic Lupus Erythematosus specific patterns
- Sjogren Syndrome
- Scleroderma Specific Patterns
- CREST Syndrome Specific Patterns
X. Interpretation: ANA Subunits
-
Systemic Lupus Erythematosus
-
Anti-dsDNA (SLE Test Sensitivity: 60%)
- Specific for lupus erythematosus
- Associated with Lupus Nephritis
- Associated with Lupus CNS Involvement
-
Anti-Smith or Anti-Sm (SLE Test Sensitivity: 20-30%)
- Highly specific for lupus erythematosus
-
Anti-ribosomal P (SLE Test Sensitivity: 20-30%)
- Highly specific for lupus erythematosus
- Associated with Lupus Psychosis
-
Anti-RNP (SLE Test Sensitivity: 30-40%)
- Associated with lupus disease activity
- Seen in all cases Mixed Connective Tissue Disease
- Anticardiolipin Antibody
- Lupus Anticoagulant
- Consider Sjogren Antibodies (Anti-SSA and Anti-SSB)
-
Anti-dsDNA (SLE Test Sensitivity: 60%)
- CREST and Scleroderma
- Anti-centromere
- Sensitivity for Scleroderma: 22-36%
- Scl-70 kD kinetochore (Anti-Topoisomerase I)
- Sensitivity for Scleroderma: 22-40%
- Anti-centromere
-
Polymyositis and Dermatomyositis
- Anti-Jo1 (sensitivity: 30%)
- Also in Raynaud's Phenomenon, pulmonary fibrosis
- Anti-Ku
- Anti-Mi2
- Anti-Jo1 (sensitivity: 30%)
- Sjogren Syndrome
- Drug Induced Lupus
- Non-specific
- Anti-ssDNA
- Non-specific and rarely indicated
- Anti-ssDNA
XI. References
- Gladman in Klippel (1997) Rheumatic Diseases p. 255-6
- Peng in Ruddy (2001) Kelley's Rheumatology, p. 161-72
- Ali (2018) Am Fam Physician 98(3): 164-70 [PubMed]
- Callegari (1995) Postgrad Med, 97(4):65-74 [PubMed]
- Lane (2002) Am Fam Physician 65(6):1073-80 [PubMed]